IRC Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Denis Vitalievich Cherednichenko
Chief executive officer
US$429.0k
Total compensation
CEO salary percentage | 100.0% |
CEO tenure | 1.8yrs |
CEO ownership | n/a |
Management average tenure | 2.9yrs |
Board average tenure | 1.9yrs |
Recent management updates
Recent updates
Returns Are Gaining Momentum At IRC (HKG:1029)
Dec 28Is IRC (HKG:1029) A Risky Investment?
Sep 02These 4 Measures Indicate That IRC (HKG:1029) Is Using Debt Reasonably Well
May 23With EPS Growth And More, IRC (HKG:1029) Is Interesting
Apr 01Under The Bonnet, IRC's (HKG:1029) Returns Look Impressive
Feb 26Here's Why IRC (HKG:1029) Can Manage Its Debt Responsibly
Nov 05IRC (HKG:1029) Is Doing The Right Things To Multiply Its Share Price
Aug 20Shareholders May Not Be So Generous With IRC Limited's (HKG:1029) CEO Compensation And Here's Why
Jun 18Returns On Capital Are Showing Encouraging Signs At IRC (HKG:1029)
May 10IRC (HKG:1029) Has A Somewhat Strained Balance Sheet
Apr 05How Much Does IRC's (HKG:1029) CEO Make?
Dec 27Reflecting on IRC's (HKG:1029) Share Price Returns Over The Last Three Years
Dec 01CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$157m |
Sep 30 2023 | n/a | n/a | -US$116m |
Jun 30 2023 | n/a | n/a | -US$76m |
Mar 31 2023 | n/a | n/a | -US$82m |
Dec 31 2022 | US$429k | US$429k | -US$88m |
Compensation vs Market: Denis Vitalievich's total compensation ($USD429.00K) is above average for companies of similar size in the Hong Kong market ($USD232.54K).
Compensation vs Earnings: Insufficient data to compare Denis Vitalievich's compensation with company performance.
CEO
Denis Vitalievich Cherednichenko (45 yo)
1.8yrs
Tenure
US$429,000
Compensation
Mr. Denis Vitalievich Cherednichenko is CEO & Executive Director of IRC Limited from July 01, 2022. He was the CEO of JSC Rosatom Healthcare, Enterprise of State Corporation Rosatom, a radiopharmaceuticals...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 1.8yrs | US$429.00k | no data | |
Chief Financial Officer | 1.8yrs | US$223.00k | no data | |
Group Head of Technologies | no data | no data | no data | |
Manager of Communications & Investor Relations | no data | no data | no data | |
Group Head of Legal & Corporate Affairs | no data | no data | no data | |
Finance Director | 9.1yrs | no data | no data | |
Consultant | 4.1yrs | US$20.00k | no data |
2.9yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 1029's management team is considered experienced (2.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 1.8yrs | US$429.00k | no data | |
Emeritus Director | no data | US$98.00k | no data | |
Independent Non-Executive Director | 1.9yrs | US$69.00k | no data | |
Non-Executive Chairman | 2.1yrs | US$126.00k | no data | |
Independent Non-Executive Director | 2.1yrs | US$69.00k | no data | |
Independent Non-Executive Director | 1.9yrs | US$69.00k | no data | |
Independent Non-Executive Director | 1.9yrs | US$69.00k | no data |
1.9yrs
Average Tenure
50yo
Average Age
Experienced Board: 1029's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.